GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vectus Biosystems Ltd (ASX:VBS) » Definitions » LT-Debt-to-Total-Asset

Vectus Biosystems (ASX:VBS) LT-Debt-to-Total-Asset

: 0.00 (As of Dec. 2023)
View and export this data going back to 2016. Start your Free Trial

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Vectus Biosystems's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.00.

Vectus Biosystems's long-term debt to total assets ratio stayed the same from Dec. 2022 (0.00) to Dec. 2023 (0.00).


Vectus Biosystems LT-Debt-to-Total-Asset Historical Data

The historical data trend for Vectus Biosystems's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vectus Biosystems Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
LT-Debt-to-Total-Asset
Premium Member Only Premium Member Only Premium Member Only 10.11 2.40 1.19 0.02 0.01

Vectus Biosystems Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
LT-Debt-to-Total-Asset Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.02 - 0.01 -

Vectus Biosystems LT-Debt-to-Total-Asset Calculation

Vectus Biosystems's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jun. 2023 is calculated as

LT Debt to Total Assets (A: Jun. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Jun. 2023 )/Total Assets (A: Jun. 2023 )
=0.027/4.63
=

Vectus Biosystems's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )/Total Assets (Q: Dec. 2023 )
=0/3.207
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vectus Biosystems  (ASX:VBS) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Vectus Biosystems LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Vectus Biosystems's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Vectus Biosystems (ASX:VBS) Business Description

Traded in Other Exchanges
N/A
Address
3-11 Primrose Avenue, Rosebery, Sydney, NSW, AUS, 2018
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company is in the process of developing a treatment for fibrosis and high blood pressure, which includes heart, kidney, and liver diseases. The company has also developed a technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories.

Vectus Biosystems (ASX:VBS) Headlines

No Headlines